Data show Ge­nen­tech paid the most to providers

Modern Healthcare - - NEWS - By Art Go­lab and Michael San­dler

Ge­nen­tech, the maker of Avastin and other pricey can­cer drugs, paid physi­cians and teach­ing hos­pi­tals more than any other drug or de­vice com­pany did in 2014, ac­cord­ing to data pub­lished last week on the CMS’ Open Pay­ments web­site.

South San Fran­cisco-based Ge­nen­tech, now a sub­sidiary of Roche, dis­closed $295.4 mil­lion in gen­eral pay­ments made in 2014, al­most four times as much as As­traZeneca, the com­pany with the next high­est tally.

The ma­jor­ity of Ge­nen­tech’s sum— $254.9 mil­lion—re­flects roy­alty pay­ments made to City of Hope, the Cal­i­for­nia com­pre­hen­sive can­cer cen­ter that holds the patents on re­search un­der­ly­ing Ge­nen­tech’s big­gest drugs, Avastin, Ri­tuxan and Her­ceptin.

The me­dian sum re­ceived by in­di­vid­ual physi­cians re­ported in the over­all data­base was $2,318.

The Dana-Farber Can­cer In­sti­tute in Bos­ton ac­cepted $15.4 mil­lion, the largest tally among U.S. teach­ing hos­pi­tals. The MD An­der­son Can­cer Cen­ter at the Univer­sity of Texas in Hous­ton ac­cepted $11.2 mil­lion, the sec­ond­high­est amount.

The data re­veal pay­ments made for re­search, gifts, speak­ing fees, meals and travel. The web­site was man­dated by the Af­ford­able Care Act to cre­ate greater trans­parency in in­dus­try pay­ments to providers. The data posted last Tues­day re­flect the first full year of re­port­ing since the ini­tia­tive launched

“Con­sumer ac­cess to in­for­ma­tion is a key com­po­nent of de­liv­ery-sys­tem re­form and mak­ing the healthcare sys­tem per­form bet­ter,” act­ing CMS Ad­min­is­tra­tor Andy Slavitt said in a news re­lease.

The CMS logged 11.4 mil­lion dis­clo­sures from 1,444 com­pa­nies for pay­ments made in 2014. They added up to $6.49 bil­lion paid to 607,000 physi­cians and 1,121 teach­ing hos­pi­tals.

Ranked by the amount of money pro­mot­ing par­tic­u­lar prod­ucts, drugs man­u­fac­tured by Ge­nen­tech occu- pied the top three spots, and seven of the top 20. The com­pany dis­closed 19,025 pay­ments worth $54 mil­lion in con­nec­tion with Ri­tuxan, a drug used to treat non-Hodgkin’s lym­phoma and chronic lym­pho­cytic leukemia.

More than 21,000 pay­ments re­lated to Avastin ac­counted for another $34.4 mil­lion of Ge­nen­tech’s tally.

The com­pany ad­di­tion­ally made 2,178 pay­ments to­tal­ing $30.6 mil­lion to pro­mote its breast-can­cer drug Her­ceptin.

Physi­cians have crit­i­cized the Open Pay­ments re­port­ing sys­tem be­cause it places a bur­den on them to check the ac­cu­racy of dis­clo­sures.

The CMS said that it is work­ing to in­crease the re­view rate.

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.